论文部分内容阅读
【案情介绍】(一)13年神话幻灭重庆啤酒的乙肝疫苗故事开始于1998年10月。当时公司斥资1 435万元收购佳辰生物52%股权。而佳辰生物,20世纪90年代初就已开始研发治疗乙肝的新药。1999年,重庆啤酒对佳辰生物增资配股。消息公布后不到两个月,重庆啤酒就一路从13.69元疯长至30元。2001年初,重庆啤酒将募集的8 710万元资金足额投放到佳辰生物中,公司所持有的佳辰生物股权也陆续增加到93.15%,重庆啤酒就此被视作乙肝
[Case introduction] (a) 13 years myth disillusionment Chongqing beer hepatitis B vaccine story began in October 1998. At that time, the company spent 14.35 million yuan to acquire 52% stake in Jia Chen Bio. The Jia Chen biological, the 20th century, early 90s has started research and development of new drugs for the treatment of hepatitis B. In 1999, Chongqing Beer Jia Ju bio-capital allotment. Less than two months after the announcement, Chongqing Beer went crazy from RMB13.69 to RMB30. Early 2001, Chongqing Beer will raise 87.1 million yuan of funds allocated to Jia Chen biological full, the company held by Jia Chen biological equity also gradually increased to 93.15%, Chongqing Beer is considered as hepatitis B